Ritter Pharmaceuticals assigns specialist as it focuses on the first FDA-approved treatment for lactose intolerance

Ritter Pharmaceuticals will seek to do make sure its first pivotal Phase 3 clinical trial of RP-G28 for lactose intolerance goes the best it can, by appointing an expert in the field of gastroenterology, William Chey, M.D., to its Medical Advisory Board.

The company developing novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases focuses on establishing the first FDA-approved treatment for lactose intolerance.

Andrew J. Ritter, co-founder and president of Ritter Pharmaceuticals, said: “Dr. Chey has provided us a great deal of input into our Phase 3 protocol design of RP-G28 for the treatment of lactose intolerance and we appreciate his continued involvement as we prepare to begin enrollment into our Phase 3 trial in early summer.”

Dr Chey also serves as a member of the Board of Trustees of the American College of Gastroenterology, the Board of Directors of the Rome Foundation and a member of the Advisory Board of the International Foundation of Functional GI Disorders.

He has been elected to “Best Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr. Chey has been inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, was inducted into the League of Research Excellence at the University of Michigan and has received the Distinguished Clinician Award from the American Gastroenterological Association.

“I look forward to working with Ritter Pharmaceuticals as the Company prepares to launch its first pivotal Phase 3 clinical trial of RP-G28 for lactose intolerance,” commented Dr. Chey. “Lactose intolerance affects approximately 40 million people in the U.S. with limited treatment options available. I believe an FDA-approved treatment for patients could greatly impact these patients’ lives.”